--- name: journal-of-the-american-society-of-nephrology description: Use when targeting the Journal of the American Society of Nephrology or deciding whether a nephrology clinical, translational, or basic study fits this venue. Encodes the journal's fit across kidney disease, dialysis, transplantation, and renal physiology, the mechanistic and evidence bar, reporting-guideline and registration requirements, ASN house style, official-submission re-check, and desk-reject heuristics. Venue-fit aid only, not clinical advice. --- # Journal of the American Society of Nephrology (journal-of-the-american-society-of-nephrology) ## Journal positioning The Journal of the American Society of Nephrology (JASN) is the American Society of Nephrology flagship, publishing high-impact nephrology research across the full evidence spectrum: clinical trials and cohorts in kidney disease, dialysis, and transplantation; translational kidney biomarker and -omics work; and basic renal physiology, cell biology, and disease-mechanism science. Its defining expectation is a **mechanistically or clinically significant advance in kidney health and disease**, with an emphasis on discovery and disease mechanism alongside rigorous clinical work — not a small single-center series or a descriptive registry slice. With its U.S. society base, JASN often anchors strongly in mechanism, novel biology, and trials that move nephrology practice. This skill is a **fit / venue-selection / re-framing** aid; it is not clinical or regulatory advice and does not replace the journal's current instructions for authors. Before submitting, re-check the live JASN author instructions. ## When to trigger - The author names JASN for a nephrology clinical, translational, or basic-science study and wants a fit/framing check. - A kidney study must be re-framed around a disease mechanism or a practice-changing nephrology question rather than a descriptive report. - The author is choosing between JASN and Kidney International (ISN flagship), or between JASN and general medicine. - The author needs the journal's reporting-guideline, registration, and basic/animal-study expectations for kidney research. ## Scope & topic fit - Chronic and acute kidney disease: CKD progression, AKI, glomerular and tubulointerstitial disease, and diabetic and hypertensive kidney disease. - Dialysis and renal replacement: hemodialysis, peritoneal dialysis, and outcomes/access research. - Kidney transplantation: immunology, rejection, allograft outcomes, and organ-preservation science. - Renal physiology and cell biology: tubular transport, podocyte and glomerular biology, fibrosis, and electrolyte/acid-base mechanism. - Translational nephrology: kidney biomarkers, genetics/genomics, single-cell and -omics atlases with disease relevance. - Clinical trials and large cohorts with kidney endpoints (eGFR/kidney failure, mortality, cardiovascular outcomes in CKD). ## Method & evidence bar - Clinical studies must be adequately powered with prespecified, patient-centered kidney endpoints; trials require prospective registration and the registration number. - The applicable reporting guideline and checklist are expected: CONSORT for trials, STROBE for observational work, PRISMA for systematic reviews, ARRIVE for animal studies. - Basic/translational work needs rigorous controls, biological replication, validated reagents/models, and blinded/randomized animal experiments where applicable. - Mechanistic claims require perturbation evidence in cells or animals plus anchoring to human kidney tissue, biofluids, or cohorts where feasible. - Effect estimates need confidence intervals and absolute as well as relative measures; causal language must match the design and model. - eGFR/biomarker methods, kidney-outcome definitions, and statistical-analysis plans must be explicit. ## Structure & house style - ASN format with a structured abstract and a significance/visual-abstract statement; re-check current article types (Original Article, Basic Research, Clinical Research, etc.) and limits on the live guide. - The introduction frames the kidney-biology or clinical gap; the discussion states the mechanistic insight or practice implication and bounds overreach. - A CONSORT/STROBE/PRISMA flow diagram is expected for the relevant clinical design; animal work reports ARRIVE-aligned detail. - Figures show representative data with statistics, N, and replication; a supplement carries full methods, the protocol/SAP, and additional experiments. ## Official-submission checklist - Before giving submission-ready advice, read `../../resources/source-basis.md` and `../../resources/official-source-map.md`; start from the ICMJE/EQUATOR and ASN anchors, then cite the current JASN page you checked. - Search the live site for "JASN American Society of Nephrology instructions for authors" and follow the current version. - Re-check article types, abstract and significance-statement format, and word/figure/reference limits. - Confirm trial registration, the reporting checklist (CONSORT/STROBE/PRISMA/ARRIVE), data/code-availability, and protocol/SAP submission. - Re-check IRB/ethics and consent, transplant-donor consent where relevant, animal-care/IACUC approval, ICMJE authorship and conflict-of-interest disclosure, funding, and AI-use disclosure. - If the live official instructions conflict with this skill, the official instructions win. ## Pre-submission self-check - [ ] The study delivers a clear kidney-disease mechanism or a practice-changing nephrology finding. - [ ] Clinical kidney endpoints are prespecified and powered; trials are registered with the number in the manuscript. - [ ] The correct reporting checklist (CONSORT/STROBE/PRISMA/ARRIVE) is completed and attached. - [ ] Basic/translational work shows controls, replication, model validation, and human anchoring. - [ ] Mechanistic claims rest on perturbation evidence, not association alone. - [ ] IRB/consent, IACUC (if animal), ICMJE disclosures, and a data-availability statement are prepared. ## Common desk-reject triggers - Single-center descriptive series or registry slice with no mechanism and no practice change. - Association-only biomarker/-omics studies with no validation cohort or functional follow-up. - Animal/cell kidney work without human relevance, replication, or ARRIVE-aligned rigor. - Missing trial registration, protocol, or the required reporting checklist. - Incremental dialysis/transplant outcome reports with limited generalizability or novelty. ## Re-routing decision - Global-perspective or epidemiology-heavy nephrology with less mechanistic depth → `kidney-international`. - Diabetic kidney disease framed primarily around endocrine/metabolic mechanism → `diabetologia` / `journal-of-clinical-endocrinology-and-metabolism`. - Critical-care AKI dominated by ICU organ-support → `critical-care-medicine` / `american-journal-of-respiratory-and-critical-care-medicine`. - Broad practice-changing nephrology trial → general medicine (`jama` / NEJM / The Lancet in the natural-science bundle). - Pure renal cell biology with no disease anchor → a basic-science venue in the natural-science bundle. ## Output format ```text [Fit] High / Medium / Low (one-line reason) [Target] Journal of the American Society of Nephrology (ASN) [Specialty tags] [Study design / reporting guideline] [Method/evidence] [Top risk] [Official items to re-check]
[Re-route suggestion] ```